mammography around June/July of 2021 that revealed black spots where she felt the sharp pain that were benign /sleeps on one side due to strong pain; Magnesium deficiency; Possible glaucoma/ white patches were seen on nerve of eye; Swollen liver/swollen liver gets smaller and smaller; Pain at ribs; Sharp chest pain "like nerve pain"; Severe symptoms of face; Sleeps on one side due to strong pain; Red spot at left arm injection site; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (Sharp chest pain "like nerve pain") and GLAUCOMA (Possible glaucoma/ white patches were seen on nerve of eye) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048A21A and 024M20A) for Revaccination with different COVID-19 vaccine. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Mar-2021, the patient experienced INJECTION SITE ERYTHEMA (Red spot at left arm injection site). On 05-Apr-2021, the patient experienced CHEST PAIN (Sharp chest pain "like nerve pain") (seriousness criterion medically significant), LIVER DISORDER (Swollen liver/swollen liver gets smaller and smaller), MUSCULOSKELETAL CHEST PAIN (Pain at ribs), FACIAL DISCOMFORT (Severe symptoms of face) and SLEEP DISORDER (Sleeps on one side due to strong pain). On 15-Jul-2021, the patient experienced GLAUCOMA (Possible glaucoma/ white patches were seen on nerve of eye) (seriousness criterion medically significant). On an unknown date, the patient experienced PAIN (mammography around June/July of 2021 that revealed black spots where she felt the sharp pain that were benign /sleeps on one side due to strong pain) and MAGNESIUM DEFICIENCY (Magnesium deficiency). At the time of the report, CHEST PAIN (Sharp chest pain "like nerve pain"), GLAUCOMA (Possible glaucoma/ white patches were seen on nerve of eye), MUSCULOSKELETAL CHEST PAIN (Pain at ribs), PAIN (mammography around June/July of 2021 that revealed black spots where she felt the sharp pain that were benign /sleeps on one side due to strong pain), MAGNESIUM DEFICIENCY (Magnesium deficiency), FACIAL DISCOMFORT (Severe symptoms of face), SLEEP DISORDER (Sleeps on one side due to strong pain) and INJECTION SITE ERYTHEMA (Red spot at left arm injection site) outcome was unknown and LIVER DISORDER (Swollen liver/swollen liver gets smaller and smaller) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Mammogram: abnormal (abnormal) revealed black spots where she felt the sharp pain that were benign. In September 2021, Antibody test: positive (Positive) have antibodies.         No concomitant medication information provided No treatment medication information provided   Patient reported that she had a mammography around June/July of 2021 that revealed black spots where she felt the sharp pain. It was ruled as benign and not cancerous. Also she reported that she sleeps on one side due to strong pain. Company comment This case concerns a 70-year-old female patient, with no reported medical history, who experienced the unexpected serious events of CHEST PAIN and GLAUCOMA. The event CHEST PAIN occurred approximately 15 days after the administration of the second dose of mRNA-1273 vaccine. Event GLAUCOMA occurred approximately 4 months after the administration of the second dose of mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This case concerns a 70-year-old female patient, with no reported medical history, who experienced the unexpected serious events of CHEST PAIN and GLAUCOMA. The event CHEST PAIN occurred approximately 15 days after the administration of the second dose of mRNA-1273 vaccine. Event GLAUCOMA occurred approximately 4 months after the administration of the second dose of mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.